CN Bio Competitors

Acelity is a global advanced wound care company, offering innovative solutions from the hospital to home that improve the lives of patients in more than 90 countries. Our mission is to change the practice of medicine with solutions that speed healing, create economic value and improve patients’ lives. Our shared values drive our company’s personality, culture and priorities by providing a framework for making decision: Customer First, Integrity, A Will to Win, One Acelity. We are the undisputed leader in negative pressure wound therapy and the market leader in collagen dressings. Acelity is headquartered in San Antonio, Texas, with nearly 5,000 employees around the globe. This channel and specific content are intended for a global audience. Patients should consult with their healthcare providers regarding their specific medical conditions, treatments, information on this channel, and risks and benefits of Acelity products. This channel is not a substitute for professional medical advice, diagnosis, or treatment. Not all Acelity products are available in all countries. Acelity is not responsible for, and does not control/endorse materials such as linked 3rd party videos, sites or ads, and makes no representations regarding their accuracy.

Emulate, Inc. is the pioneer of Organ-on-a-Chip technology, enabling researchers to accurately replicate human tissue function and disease biology through next generation in vitro models. From target discovery to IND submission, Emulate aims to ignite a new era in human health research—one that reduces animal testing, cuts drug development costs, and accelerates the delivery of life-saving treatments. Emulate’s Organ-Chip platforms, consumables, and organ models help the world’s leading pharmaceutical, biotech, and academic teams generate human-relevant data that advance safer, more effective therapies.

REPROCELL supports nearly the entire workflow of stem cell research and pre-clinical drug development. Our unique portfolio includes access to human tissues (BioServe) and human tissue testing (Biopta), in addition to stem cell culture media, reprogramming technologies, reagents, and iPSC-derived cell types (Stemgent). With our deep knowledge of stem cell biology, bioengineered (3D) tissue models (Alvetex) cell differentiation, and pharmacology, REPROCELL is a recognized leader in cutting-edge tools and services to accelerate regenerative medicine and drug development. The newly formed REPROCELL Medical business unit is developing a suite of reagents and services to meet the growing need for clinical-grade products and services that are appropriate for regenerative medicine. In addition, our labs offer diagnostic services for a variety of tests related to tissue compatibility and other biomarkers. And finally, REPROCELL also offers a GMP iPSC master cell bank manufacturing service. *** REPROCELL went public on the Japan JASDAQ in June 2013. Stemgent, BioServe and Reinnervate became parts of REPROCELL in 2014. Biopta was then acquired in 2015.